Operational Performance (Gurgaon Facility) Q2 FY27

  • IP Volumes: Increased 12.0% YoY to 9,787 patients
  • ARPOB: Increased to ₹86,631, up 6.6% YoY
  • Occupancy: Improved to 68.1%, up 398 bps YoY
  • ALOS: Reduced to 3.52 days from 3.67 days YoY
  • Bed Capacity: 700 beds (600 census beds, 100 non-census beds)
  • Operational Beds: 550 beds

Financial Performance (Standalone) Q2 FY27

  • Revenue from Operations: ₹29,844 Lacs, up 14.5% YoY
  • EBITDA: ₹7,096 Lacs, up 21.8% YoY
  • EBITDA Margin: 23.8%, expanded 141 bps YoY
  • PAT: ₹4,043 Lacs, up 25.9% YoY
  • PAT Margin: 13.5% vs 12.3% YoY

Financial Performance (Consolidated) Q2 FY27

  • Revenue from Operations: ₹31,104 Lacs, up 13.2% YoY
  • EBITDA: ₹6,289 Lacs, up 7.9% YoY
  • Adjusted EBITDA: ₹7,150 Lacs, up 22.7% YoY (excludes Revenue and EBITDA losses of Raipur Unit)
  • Adjusted EBITDA Margin: 23.3%, expanded 210 bps YoY
  • PAT: ₹3,110 Lacs, up 3.7% YoY
  • Diluted EPS: ₹1.96, up 3.7% YoY

Half-Yearly Performance (Consolidated) H1 FY27

  • Revenue from Operations: ₹59,836 Lacs, up 13.0% YoY
  • PAT: ₹6,254 Lacs, up 22.2% YoY
  • Diluted EPS: ₹3.94, up 21.6% YoY

Expansion and Growth Initiatives

  • Raipur Hospital: 300+ bed super speciality hospital commenced operations in July 2026
  • South Delhi Hospital: MSA executed for 650+ bed super speciality hospital (expected operational date Q4 FY29/FY30)
  • Capacity Target: ~2,000 beds by 2030 (currently ~1,000 beds)
  • International Operations: 80-bed 'Artemis Curepipe Hospital' (FY24) and 110-bed 'Artemis Cascavelle Hospital' in Mauritius (FY27)
  • Gurgaon Expansion: Third tower added, taking capacity to 700 beds; Platinum Green Building Certification enables 15% FAR increase; purchase of additional FAR to 2.15 could add ~250+ beds (total 950-1,000 beds)
  • Fundraising: Proposed ~₹700 crore fund raise approved by shareholders

Clinical and Operational Highlights

  • Centers of Excellence: 14 centers across 40+ specialties
  • High-Acuity Revenue: ~60% of revenue from high-acuity specialties
  • International Patients: 27-30% of revenue from international patients spanning 150+ countries
  • Technology: Advanced medical technologies including CyberKnife M6, da Vinci Robotic Surgical System, CUVIS JOINT Robotic System
  • New Facility: Little Artemis - dedicated children's and women's hospital opened within Gurugram campus

Corporate Governance

  • Chairman: Mr. Onkar Kanwar
  • Managing Director: Dr. Devlina Chakravarty
  • Board: Includes 5 non-executive directors and 5 independent directors
  • Management Team: Led by CFO Sanjiv Kumar Kothari, Chief Medical Services Dr. Manju Aggarwal, and Company Secretary Poonam Makkar

Shareholding Pattern (as on September 30, 2026)

  • Promoters: 58.4% (Constructive Finance Pvt Ltd)
  • FII: 12.0% (International Finance Corporation)
  • Government: 6.2% (Governor of Kerala 4.3%, Kerala State Industrial Development Corporation 1.9%)
  • Director: 2.8% (Devlina Chakravarty)
  • DII: 1.6% (HSBC Mutual Fund 0.8%, Bank of India 0.8%)

Balance Sheet Overview (H1 FY27 Consolidated)

  • Total Shareholders Funds: ₹99,566 Lacs
  • Total Loans: ₹24,204 Lacs
  • Net Fixed Assets: ₹96,577 Lacs
  • Cash and Bank Balances: ₹26,712 Lacs
  • Net Current Assets: (₹1,278) Lacs

ESG and CSR Initiatives

  • FY27 Target: ~30% cut in Scope 2 emissions through off-site solar
  • Community Reach: 58,960 people reached through community programmes
  • Policy: Anti-bribery & anti-corruption policy covers directors, KMPs, employees and third parties

Forward-Looking Statements

The presentation contains forward-looking statements regarding strategic initiatives and future business developments, subject to risks including market conditions, regulatory trends, currency movements, competitive pressures, and technological developments.